[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Beldner MA, Sherman CA, Green MR, Garrett-Mayer E, Chaudhary U, Meyer ML, Kraft AS, Montero AJ: Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer; 2007 Dec 20;7:231
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer.
  • BACKGROUND: A platinum doublet is the current standard treatment for good performance status patients with advanced non-small cell lung cancer (NSCLC) and extensive stage small cell lung cancer (SCLC) with good performance status.
  • However, platinum-based treatment may be associated with significant toxicities, therefore alternative platinum-free combinations should be investigated.
  • Therefore, the aim of this study was to evaluate the optimal dosage and the maximal tolerated dose (MTD) of topotecan and vinorelbine in patients with relapsed or refractory non-small cell or small cell lung cancer administered on an alternate dosing schedule.
  • METHODS: From February, 2004 to March, 2007 eighteen patients with advanced or recurrent NSCLC or SCLC previously treated with chemotherapy were enrolled.
  • Patients were heavily pretreated with 22% having received at least 3 prior lines of chemotherapy.
  • Non-hematological toxicities were manageable.
  • This doublet provides a potentially active non-platinum containing doublet for the treatment of patients with advanced SCLC and NSCLC.
  • [MeSH-major] Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Topotecan / administration & dosage. Vinblastine / analogs & derivatives
  • [MeSH-minor] Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 16):62-6; discussion 71-2 [10585010.001]
  • [Cites] Lung Cancer. 2007 Jul;57(1):84-8 [17399850.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Sep;48(3):188-96 [11592339.001]
  • [Cites] Oncology. 2001;61 Suppl 1:35-41 [11598413.001]
  • [Cites] Oncology. 2001;61 Suppl 1:47-54 [11598415.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):394-9 [11606103.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Am J Clin Oncol. 2002 Aug;25(4):337-9 [12151959.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3 Pt 2):S3-7 [13129489.001]
  • [Cites] Lung Cancer. 2003 Aug;41 Suppl 4:S3-8 [14565508.001]
  • [Cites] Oncologist. 2004;9 Suppl 2:16-23 [15161987.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1618-26 [1651993.001]
  • [Cites] Eur J Cancer. 1993;29A(12):1720-2 [8398301.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1 Suppl 5):S5-12-S5-18 [9122737.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2090-6 [9164222.001]
  • [Cites] Semin Oncol. 1997 Dec;24(6 Suppl 20):S20-34-S20-41 [9425959.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1414-9 [9552045.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2459-65 [9667264.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):658-67 [10080612.001]
  • [Cites] Oncologist. 2004;9 Suppl 6:25-32 [15616147.001]
  • [Cites] Oncol Rep. 2005 Dec;14(6):1547-51 [16273254.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2044-51 [16648504.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):104-9 [17071939.001]
  • [Cites] J Thorac Oncol. 2006 Mar;1(3):270-8 [17409868.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):2086-92 [17513814.001]
  • [Cites] J Thorac Oncol. 2007 Jun;2(6):526-30 [17545848.001]
  • [Cites] Br J Cancer. 2001 May 4;84(9):1166-71 [11336465.001]
  • (PMID = 18096059.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00287963
  • [Publication-type] Clinical Trial, Phase I; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 7M7YKX2N15 / Topotecan; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ PMC2241632
  •  go-up   go-down


2. Kimura H, Iizasa T, Ishikawa A, Yoshino M, Shingyouji M, Kimura M, Hirata T, Odaka A, Matsubayasi K: Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report. J Med Case Rep; 2008;2:372

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report.
  • To control ascites, drainage and intra-abdominal chemotherapy are often used in those patients but eradication of ascites is difficult and prognosis is poor.
  • Abdominocentesis revealed peritoneal carcinomatosis resulting from abdominal recurrence from lung cancer.
  • After the drainage of ascites, we intraperitoneally infused activated killer cells and dendritic cells from the patient's tumor-draining lymph nodes, together with 4.5 x 105U interleukin-2 in 50 ml saline by 2.1 ml/hour infuser balloon.Drastic decreases in the tumor cell count and in ascite retention were observed after several courses of ascites drainage, intravenous infusion and intraperitoneal immunotherapy.
  • The plasma protein level was maintained during the treatment notwithstanding the repeated drainage of ascites.
  • Cell surface marker analysis, cytotoxic activities against autologous tumor cells and interferon-gamma examination of ascites suggested the possibility that these effects were mediated by immunological responses of activated killer cells and dendritic cells infused intraperitoneally.
  • CONCLUSION: Combination of local administration of immune cells and infusion of concentrated cell free ascites may be applicable for patients afflicted with refractory ascites.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Jul 1;92(1):71-6 [11443611.001]
  • [Cites] Cancer Invest. 2002;20(7-8):1118-22 [12449746.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):799-806 [12610177.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3B):2317-21 [10472351.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1A):85-94 [15816523.001]
  • [Cites] Ann Surg. 2007 Apr;245(4):597-603 [17414609.001]
  • [Cites] Cancer Invest. 2005;23(2):155-72 [15813509.001]
  • (PMID = 19055844.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2613411
  •  go-up   go-down


3. Ebert BL, Niemierko E, Shaffer K, Salgia R: Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist; 2003;8(1):69-75
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer.
  • The use of chemotherapy for the treatment of brain metastases arising from lung cancer has been limited by poor efficacy and high toxicity.
  • Temozolomide, an orally bioavailable alkylating agent that crosses the blood-brain barrier, has activity against brain metastases from both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) when used as a single agent, but response rates are low.
  • We report a case of a patient with SCLC with recurrent brain metastases after treatment with multiple chemotherapeutic regimens and whole-brain radiation therapy (WBRT) who was treated with temozolomide (150 mg/m(2) for 5 days in a 28-day cycle) and oral etoposide (50 mg/m(2) for 10 days in a 28-day cycle).
  • A second patient with NSCLC and brain metastases who progressed after treatment with chemotherapy and WBRT was treated with temozolomide (150 mg/m(2) for 5 days in a 28-day cycle) and gemcitabine (1,000 mg/m(2) weekly for 2 weeks in a 3- week cycle).
  • The combination of temozolomide with other chemotherapeutic agents represents a promising strategy for treating patients with lung cancer and recurrent brain metastases and merits further study.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / secondary. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / secondary. Dacarbazine / analogs & derivatives. Dacarbazine / pharmacology. Lung Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Etoposide / administration & dosage. Female. Humans. Middle Aged. Prognosis. Treatment Outcome


Advertisement
4. Kawasaki Y, Kato K, Kobayashi K, Yano S, Saito S, Fukuda M, Miyata M, Shimizu E: [Successful outpatient treatment with chemotherapy of weekly gemcitabine and vinorelbine for a patient with recurrent lung cancer]. Gan To Kagaku Ryoho; 2002 Jan;29(1):107-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful outpatient treatment with chemotherapy of weekly gemcitabine and vinorelbine for a patient with recurrent lung cancer].
  • A 68-year-old man with recurrent lung cancer was treated with chemotherapy of weekly gemcitabine and vinorelbine on an outpatient basis.
  • After 2 cycles of the regimen, shadows in the lung completely disappeared.
  • During this treatment, the patient's condition was good.
  • [MeSH-major] Adenocarcinoma / drug therapy. Ambulatory Care. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Aged. Drug Administration Schedule. Humans. Male. Quality of Life

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11816464.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


5. Kawasaki Y, Kato K, Kobayashi K, Yano S, Saito S, Tokushima T, Miyata M, Matsumoto S, Mikami M, Yasuda K, Hitsuda Y, Shimizu E: [Successful treatment of weekly paclitaxel for a patient with recurrent lung cancer]. Gan To Kagaku Ryoho; 2002 Jan;29(1):103-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment of weekly paclitaxel for a patient with recurrent lung cancer].
  • A 44-year-old man with recurrent lung cancer was readmitted to the hospital for chemotherapy.
  • He was first treated by chemotherapy of CDDP + etoposide, after which the chemotherapy was changed to a regimen of weekly paclitaxel because of his desire to work.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / administration & dosage
  • [MeSH-minor] Adult. Drug Administration Schedule. Humans. Male. Quality of Life

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11816463.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. Wu C, Hao H, Li L, Zhou X, Guo Z, Zhang L, Zhang X, Zhong W, Guo H, Bremner RM, Lin P: Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol; 2009 Jan;4(1):30-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients.
  • BACKGROUND: Enumeration of circulating tumor cells (CTCs) may be valuable for lung cancer treatment and monitoring cancer patient relapse.
  • In the present study we report clinical significance of lung cancer CTC.
  • METHODS: CTCs were enriched from peripheral blood of 47 lung cancer patients by means of a modified enrichment strategy, followed by identification with immunofluorescence staining using anticytokeratins 18 and 19 monoclonal antibodies.
  • RESULTS: A control group consisted of 18 healthy donors and 13 nonmalignant pulmonary tuberculosis patients had no positive subject detected.
  • Among 41 newly diagnosed and 6 recurrent lung cancer patients (3 stage I-II, 22 stage III and 22 stage IV) including 27 adenocarcinoma (ADC), 7 squamous cell carcinoma and 13 small cell lung cancer (SCLC), positive detection rate of newly diagnosed patients with CTC >/=2/7.5 ml blood was 78% (ADC stage III), 75% (squamous cell carcinoma stage III) and 60% (SCLC stage III), respectively.
  • Recurrent patients showed highest detection sensitivity of 83%.
  • A small scale follow-up study was performed on 12 patients following 2 courses of first line chemotherapy.
  • CONCLUSIONS: Results of the present study suggest potential clinical utilities of CTC enumeration on lung cancer patients in terms of rapid evaluation of chemotherapy effect in real time and monitoring lung cancer recurrence.
  • A large scale of study which is necessary for further validation of the significance of lung cancer CTC is being performed.
  • [MeSH-major] Biomarkers, Tumor / blood. Lung Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplastic Cells, Circulating / pathology. Small Cell Lung Carcinoma / pathology
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antibodies, Monoclonal. Carcinoma, Large Cell / blood. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Case-Control Studies. Follow-Up Studies. Humans. Immunoenzyme Techniques. Keratin-18 / blood. Prognosis. Sensitivity and Specificity. Tuberculosis, Pulmonary / blood. Tuberculosis, Pulmonary / pathology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096303.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Keratin-18
  •  go-up   go-down


7. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, Iizasa T, Nakayama T, Taniguchi M, Fujisawa T: A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res; 2005 Mar 1;11(5):1910-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
  • PURPOSE: Human Valpha24 natural killer T (NKT) cells bearing an invariant Valpha24JalphaQ antigen receptor, the counterpart of murine Valpha14 NKT cells, are activated by a specific ligand, alpha-galactosylceramide (alphaGalCer, KRN7000), in a CD1d-dependent manner. I.v. administration of alphaGalCer-pulsed dendritic cells (DC) induces significant activation and expansion of Valpha14 NKT cells in the lung and resulting potent antitumor activities in mouse tumor metastatic models.
  • We did a phase I dose escalation study with alphaGalCer-pulsed DCs in lung cancer patients.
  • EXPERIMENTAL DESIGN: Patients with advanced non-small cell lung cancer or recurrent lung cancer received i.v. injections of alphaGalCer-pulsed DCs (level 1: 5 x 10(7)/m(2); level 2: 2.5 x 10(8)/m(2); and level 3: 1 x 10(9)/m(2)) to test the safety, feasibility, and clinical response.
  • [MeSH-major] Antineoplastic Agents / immunology. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / immunology. Dendritic Cells. Galactosylceramides / immunology. Galactosylceramides / therapeutic use. Killer Cells, Natural / immunology. Lung Neoplasms / drug therapy. Lung Neoplasms / immunology
  • [MeSH-minor] Aged. Cell Culture Techniques. Cell Proliferation. Female. Humans. Immunotherapy. Infusions, Intravenous. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756017.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Galactosylceramides; 158021-47-7 / KRN 7000
  •  go-up   go-down


8. Pinto CA, Carvalho PE, Antonângelo L, Garippo A, Da Silva AG, Soares F, Younes R, Beyruti R, Takagaki T, Saldiva P, Vollmer RT, Capelozzi VL: Morphometric evaluation of tumor matrix metalloproteinase 9 predicts survival after surgical resection of adenocarcinoma of the lung. Clin Cancer Res; 2003 Aug 1;9(8):3098-104
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphometric evaluation of tumor matrix metalloproteinase 9 predicts survival after surgical resection of adenocarcinoma of the lung.
  • PURPOSE: Recently, several matrix metalloproteinases (MMPs) have shown promise as prognosticators in non-small cell lung cancer.
  • EXPERIMENTAL DESIGN: We examined MMP-9 and several other markers in tumor tissues from 152 patients with surgically excised adenocarcinomas of the lung.
  • Their preoperative clinical stages were T(1-4)N(0)M(0); however, pathological exam of their resected tissues demonstrated that 33 were stage II, and 64 were stage III.
  • We used immunohistochemistry and morphometry to evaluate the amount of tumor staining for MMP-9, and the outcome for our study was survival time until death from recurrent lung cancer.
  • RESULTS: Multivariate Cox model analysis demonstrated that pathological stage was significantly related to survival time (P < 0.01), but quantitative staining of the tumor for MMP-9 added prognostic information (P < 3.0 x10(-16)) and was more strongly prognostic than pathological stage.
  • In the subset of pathological stage I patients, staining for MMP-9 was also significantly associated with survival (P < 1.0 x10(-6)), and a cutpoint at the median staining of 11.2% for MMP-9 divided them into two groups with distinctive survival times.
  • Those with MMP-9 > 11.2% had a median survival time of just 11 months.
  • Those with MMP-9 < 11.2% had not reached a median survival and had a mean survival time of >62 months.
  • CONCLUSIONS: Tumor staining for MMP-9 in resected adenocarcinoma of the lung is strongly related to survival.
  • Patients with >11.2% staining in their tumors comprise a subset with a high hazard for dying of lung cancer and may be an appropriate target for prospective studies of adjuvant chemotherapy after surgical resection.
  • [MeSH-major] Adenocarcinoma / enzymology. Lung Neoplasms / enzymology. Matrix Metalloproteinase 9 / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Male. Middle Aged. Prognosis. Proportional Hazards Models. Time Factors. Tumor Suppressor Protein p53 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12912961.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


9. Asai M, Minami S, Komuta K, Kido T: [Improvement in quality of life with vinorelbine as a single agent in two patients with recurrent lung cancer]. Gan To Kagaku Ryoho; 2000 Nov;27(13):2105-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Improvement in quality of life with vinorelbine as a single agent in two patients with recurrent lung cancer].
  • Two patients with lung cancer that recurred after surgery and chemotherapy were administered vinorelbine (20 mg/m2) as a single agent on days 1 and 8 every 4 weeks.
  • Patient 1 had recurrences in both lung lobes and metastases in the bone and liver after surgery, while patient 2 had a recurrence in the left lung lobe and metastases in the brain and liver after prior chemotherapy.
  • In both patients, vinorelbine treatment improved several clinical indicators of cancer symptomatology including serum LDH, levels of other clinical blood tests, as well as a subjective assessment of the quality of life (QOL).
  • Because recurrent lung cancer patients generally have a poor performance status, chemotherapy for these patients is thought to worsen the QOL and increase hospital stays.
  • The present report suggests that vinorelbine, as a single agent, might improve the QOL and make it possible to treat recurrent lung cancer patients on an outpatient basis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Quality of Life. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives
  • [MeSH-minor] Aged. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11103242.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


10. Okagawa T, Uchida T, Suyama M: [A case of postoperative recurrent lung cancer with long survival due to gefitinib efficacy]. Gan To Kagaku Ryoho; 2007 Nov;34(11):1841-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of postoperative recurrent lung cancer with long survival due to gefitinib efficacy].
  • A 70-year-old woman underwent a right middle lobectomy and partial resection of right upper lobe for lung cancer.
  • We diagnosed it as a recurrence of the lung cancer.
  • Although we recommended chemotherapy, she hesitated and went without treatment for about 1 year.
  • Then, 1 month after beginning gefitinib, her serum CEA level normalized and the recurrent lesion disappeared on chest CT.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Aged. Carcinoembryonic Antigen / blood. Drug Administration Schedule. Female. Humans. Survivors

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030020.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


11. Takahashi N, Tokomatsu K, Sugawara H: [Assessment of the therapy for the recurrent lung cancer after pulmonary operation]. Kyobu Geka; 2001 Sep;54(10):815-21; discussion 821-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of the therapy for the recurrent lung cancer after pulmonary operation].
  • As is generally known, pulmonary carcinomas have not good prognosis.
  • Therefore, the opportunity to encounter recurrent cases after pulmonary operations is increasing more and more.
  • In this research we compared the three groups, group A; re-operations were performed for recurrent pulmonary cancers (eleven cases), group B; chemo- and/or irradiation-therapy were performed (eleven cases), group C; only conservative therapies were received (twenty-one cases).
  • From that conclusion we could indicate the therapeutic policy for recurrent pulmonary carcinomas as follows. in contralateral recurrent case, lesser resection (wedge/segment) with VATS as possible even if the same side recurrent case, aggressive removal of cancer (GRF glue is useful for protection against air leakage.) without lymph node dissection, as the same concept of metastatic lung tumor in case of non-operative indication, consideration of chemotherapy and/or irradiation, (especially hypotonic therapy was effective against carcinomatous hydrothorax.) in a difficult case for chemotherapy and/or irradiation, BAI is one of methods which ought to be tried.
  • [MeSH-major] Lung Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Pneumonectomy

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11554069.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Takaoka K, Kimura B, Aikawa A, Tokimitsu S, Hashizume M, Kidokoro T, Katou K, Takano T, Yamagishi M, Uchikado M, Itou S, Okano Y, Hanawa Y, Yagi M: [A case of postoperative recurrent lung cancer with chronic renal failure and respiratory failure successfully treated with gefitinib]. Gan To Kagaku Ryoho; 2005 Jan;32(1):73-6
MedlinePlus Health Information. consumer health - Respiratory Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of postoperative recurrent lung cancer with chronic renal failure and respiratory failure successfully treated with gefitinib].
  • We administered gefitinib to a patient after considering his request to be treated with the drug.
  • Fortunately, he responded favorably to the treatment and did not show signs of serious adverse effects or deterioration of renal functions.
  • The patient was a 69-year-old male who visited an outpatient clinic because of chronic renal failure and was diagnosed with primary lung cancer.
  • He then underwent an operation for lung cancer, but because it had progressed to stage IV the lesion was not completely resected.
  • The patient was unable to receive effective chemotherapy due to the prior chronic renal failure.
  • The patient was administered 250 mg of gefitinib orally, which was effective in reducing the tumor, improving his QOL, and prolonging his survival time.
  • With the lack of literature on administering gefitinib to patients with chronic renal failure and evidence supporting the effectiveness of this treatment, the physician in charge should obtain the patient's informed consent before initiating treatment using this anticancer drug.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Kidney Failure, Chronic / complications. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Quinazolines / therapeutic use. Respiratory Insufficiency / complications


13. Sasaki H, Endo K, Okuda K, Kawano O, Kitahara N, Tanaka H, Matsumura A, Iuchi K, Takada M, Kawahara M, Kawaguchi T, Yukiue H, Yokoyama T, Yano M, Fujii Y: Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res Clin Oncol; 2008 May;134(5):569-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer.
  • To evaluate the epidermal growth factor receptor (EGFR) protein expression, gene mutations and amplification as predictors of clinical outcome in patients with non-small-cell lung cancer (NSCLC) receiving gefitinib, we have performed fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC).
  • We investigated the EGFR amplification and EGFR protein expression statuses in 27 surgically treated non-small-cell lung cancer (NSCLC) cases.
  • EGFR mutations were found from 15/27 lung cancer patients.
  • Smoking status (never smoker vs. smoker, P=0.0032), and pathological subtypes (adenocarcinoma vs. non-adenocarcinoma, P=0.0011), but not EGFR amplification (P=0.1278), were correlated with survival of lung cancers.
  • We have also evaluated the EGFR mutation status and clinico-pathological features for 27 NSCLC patients who had undergone surgery followed by treatment with gefitinib at the National Hospital Organization, Kinki-chuo Chest Medical Center.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / genetics. Drug Resistance, Neoplasm / genetics. Genes, erbB-1. Lung Neoplasms / genetics. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Gene Amplification. Gene Dosage. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Japan. Kaplan-Meier Estimate. Male. Middle Aged. Mutation. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Retrospective Studies. Smoking / adverse effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3908-14 [16818686.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Cancer. 2007 May 1;109(9):1836-44 [17387741.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):857-65 [15681531.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1167-73 [15709185.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1103-9 [15020612.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2924-9 [15837743.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7241-4 [15492241.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):136-43 [14734462.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44 [16467097.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):375-84 [16199108.001]
  • [Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15 [11597399.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6829-37 [15998907.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):180-4 [16003726.001]
  • [Cites] Science. 2004 Aug 20;305(5687):1163-7 [15284455.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] J Thorac Oncol. 2007 May;2(5):423-9 [17473658.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8919-23 [15604253.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2513-20 [15738541.001]
  • [Cites] BMC Cancer. 2006 Dec 21;6:295 [17184525.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12 (8):2538-44 [16638863.001]
  • (PMID = 17932690.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


14. Oshita F, Nishio K, Kameda Y, Mitsuda A, Ikehara M, Tanaka G, Yamada K, Nomura I, Noda K, Arai H, Ito H, Nakayama H: Increased expression levels of p53 correlate with good response to cisplatin-based chemotherapy in non-small cell lung cancer. Oncol Rep; 2000 Nov-Dec;7(6):1225-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression levels of p53 correlate with good response to cisplatin-based chemotherapy in non-small cell lung cancer.
  • In order to determine whether expression of the tumor suppressor gene p53 in non-small cell lung cancer (NSCLC) correlates with chemotherapeutic response, resected tumors from 18 patients with recurrent lung cancer who had undergone complete resection and received chemotherapy after the initial tumor recurrence were subjected to p53 immunostaining.
  • Histological examination of the resected tumors revealed 11 adenocarcinomas, 6 squamous cell carcinomas and one adenosquamous cell carcinoma.
  • All patients received cisplatin-based chemotherapy after recurrence.
  • No patient in group 1 achieved response to chemotherapy whereas 2 and 3 in group 2 achieved complete and partial responses, respectively.
  • The chemotherapy response rate of group 2 (56%) was significantly higher than that of group 1 (0%, p=0.009).
  • The times to reoccurrence after tumor resection of group 2 was significantly better than that of group 1 (log-rank p=0.019, Wilcoxon p=0.042), and survival after chemotherapy of group 2 was also significantly better than that of group 1 (log-rank p=0.023, Wilcoxon p=0.034).
  • It is suggested that high p53 expression levels in tumors correlate with both good response to cisplatin-based chemotherapy and good survival of patients with advanced NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / metabolism. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Disease-Free Survival. Female. Gene Expression. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Mitomycin / administration & dosage. Survival Analysis. Treatment Outcome. Vindesine / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. VINDESINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11032919.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 50SG953SK6 / Mitomycin; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine; UM20QQM95Y / Ifosfamide; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


15. Kitagawa C, Saka H, Adachi T, Kajikawa S, Mori K, Kogure Y, Oki M, Shimokata K: A dose finding and PK/PD study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial. J Clin Oncol; 2009 May 20;27(15_suppl):e13517

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dose finding and PK/PD study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial.
  • : e13517 Background: Amrubicin (AMR) is a potent topoisomerase II inhibitor, and a promising agent for both small cell and non-small cell lung cancer.
  • The purpose of this study was to evaluate the safety and tolerability of AMR, to determine the recommended weekly dose, and to conduct a PK/PD study in patients with chemotherapy-refractory or recurrent lung cancer.
  • METHODS: Refractory or relapsed non-small cell and small cell lung cancer patients after 1 or 2 regimens, younger than 80 and with adequate main organ functions were eligible.
  • Patients were 7 small cell lung cancer and 9 non-small cell lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961311.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Takahashi N, Tsunematsu K, Suzuki A, Shioya M: [Surgical treatment for recurrent pulmonary carcinoma including same and different cell types]. Kyobu Geka; 2010 Oct;63(11):930-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment for recurrent pulmonary carcinoma including same and different cell types].
  • There are many problems regarding diagnosis of the next lung cancer as local recurrence, metastasis or 2nd primary and there is a limit to only morphologic findings.
  • From the above-mentioned facts, this study distinguished the recurrent resected lung tumors between same (As: n = 19) and different (Ah: n = 8) cell types from the 1st lung cancer.
  • These 2 groups were compared each other and with group B, which was treated to recurrent lung cancer only with chemotherapy and/or radiation, and group C, which was not treated.
  • There were long intervals between the 1st and the 2nd operations (overall mean 56.1+/- 45.6 month, max 190 month), therefore we must follow up on patients undergone resection of lung cancer at the long-term periods.
  • Recent amelioration of chemotherapy and radiotherapy can keep patients with recurrent lung cancer survive by over 5 years.
  • It is important not only to perform an aggressive 2nd operation for recurrent lung cancer but also to estimate post-2nd-operative lung function for selection of operative procedure and to prefer multidisciplinary treatment.
  • [MeSH-major] Lung Neoplasms / surgery
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / therapy. Neoplasms, Second Primary / therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20954345.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Bekki J, Katayama S, Orihashi N, Nakagi H, Yamada A: [A case of recurrent lung cancer successfully treated using ambulatory chemotherapy with vinorelbine]. Gan To Kagaku Ryoho; 2002 Mar;29(3):431-4
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent lung cancer successfully treated using ambulatory chemotherapy with vinorelbine].
  • She had previously suffered from stage IA lung adenocarcinoma and undergone a right upper lobe resection.
  • Combination chemotherapy with cisplatin (CDDP) and docetaxel (TXT) failed to produce an antitumor effect.
  • The treatment was changed to ambulatory chemotherapy with vinorelbine (VNB) at 20 mg/m2 weekly.
  • As VNB is easy to administer, it will be applicable in ambulatory chemotherapy administered with consideration of the patients quality of life.
  • [MeSH-major] Adenocarcinoma / drug therapy. Ambulatory Care. Antineoplastic Agents, Phytogenic / administration & dosage. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives
  • [MeSH-minor] Drug Administration Schedule. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11915734.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


18. Oshita F, Kameda Y, Nishio K, Tanaka G, Yamada K, Nomura I, Nakayama H, Noda K: Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer. Oncol Rep; 2000 May-Jun;7(3):491-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer.
  • In order to determine whether expression of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer (NSCLC) correlates with chemotherapeutic response, resected tumors from 22 patients with recurrent lung cancer who had undergone complete resection and received chemotherapy after the initial tumor recurrence were subjected to p27 immunostaining.
  • Histological examination of the resected tumors revealed 14 adenocarcinomas, 7 squamous cell carcinomas and one adenosquamous cell carcinoma.
  • All but one patient received platinum-based chemotherapy after recurrence.
  • Only one in group 1 achieved a partial response (PR) in chemotherapy whereas 2 and 4 in group 2 achieved complete and PRs, respectively.
  • The chemotherapy response rate of group 2 (54%) was significantly higher than that of group 1 (9%, p=0.022).
  • The times to recurrence after tumor resection of the 2 groups did not differ significantly (log-rank p=0.23, Wilcoxon p=0.
  • 32), but survival after chemotherapy of group 2 was significantly better than that of group 1 (log-rank p=0.045, Wilcoxon p=0.028).
  • It is suggested that high p27 expression levels in tumors may predict the good responses to platinum-based chemotherapy for NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Cell Cycle Proteins. Cisplatin / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Microtubule-Associated Proteins / analysis. Tumor Suppressor Proteins
  • [MeSH-minor] Cyclin-Dependent Kinase Inhibitor p27. Cyclin-Dependent Kinases / antagonists & inhibitors. Enzyme Inhibitors / analysis. Follow-Up Studies. Humans. Immunohistochemistry. Predictive Value of Tests. Recurrence. Retrospective Studies. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10767357.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Enzyme Inhibitors; 0 / Microtubule-Associated Proteins; 0 / Tumor Suppressor Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.11.22 / Cyclin-Dependent Kinases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Yamada K, Wasa J, Sugiura H, Horio Y: [A case of multiple pyomyositis after chemotherapy for lung cancer]. Gan To Kagaku Ryoho; 2006 Jun;33(6):837-40
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of multiple pyomyositis after chemotherapy for lung cancer].
  • We here describe a case of multiple pyomyositis in a 62-year-old man who had systemic chemotherapy for recurrent lung cancer.
  • Surgical drainage as well as intravenous administration of antibiotics worked very well and improved clinical symptoms in a few weeks after the treatments.
  • Pyomyositis should be kept in mind as one of the adverse effects after chemotherapy for malignant tumors.
  • [MeSH-major] Adenocarcinoma / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / complications. Myositis / etiology. Staphylococcal Infections / etiology


20. Kaneko K, Yoshida T, Hiyama J, Ono K, Omagari J: Chest wall and axillary lymph node FDG uptake associated with cancer vaccine therapy for lung cancer. Clin Nucl Med; 2010 Sep;35(9):729-30
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chest wall and axillary lymph node FDG uptake associated with cancer vaccine therapy for lung cancer.
  • Cancer vaccines are now undergoing clinical investigations, and clinical trials of therapeutic cancer vaccines have been conducted mainly for advanced cancer patients.
  • We experienced 2 cases of multifocal F-18 fluoro-2-deoxy-D-glucose uptake in the chest wall and axillary lymph nodes associated with personalized peptide vaccine therapy for recurrent lung cancer.
  • In this article, we report fluoro-2-deoxy-D-glucose -positron emission tomography and positron emission tomography/computed tomography findings.
  • [MeSH-major] Axilla / radionuclide imaging. Cancer Vaccines / adverse effects. Cancer Vaccines / therapeutic use. Fluorodeoxyglucose F18 / pharmacokinetics. Lung Neoplasms / drug therapy. Lymph Nodes / radionuclide imaging. Thoracic Wall / radionuclide imaging
  • [MeSH-minor] Aged. Female. Humans. Male. Positron-Emission Tomography. Recurrence. Small Cell Lung Carcinoma / drug therapy. Small Cell Lung Carcinoma / radionuclide imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20706056.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


21. Werner-Wasik M, Pequignot E, Leeper D, Hauck W, Curran W: Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys; 2000 Oct 1;48(3):689-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy.
  • PURPOSE: To identify in a multivariate analysis treatment-related factors predisposing patients (pts) with lung cancer to acute esophagitis, expressed as a severity grade or Esophagitis Index (EI).
  • Charts, toxicity forms and digitally reconstructed radiographs (DRRs) of all pts with lung cancer who received thoracic radiotherapy (RT) between 11/95 and 1/99 were reviewed.
  • Esophagitis grades for each time point were verified by review of weekly physician and nursing treatment notes, hospital discharge summaries and referring physician notes and then plotted on graph against time.
  • Pts were included in the analysis (n = 105) if they fulfilled the following criteria: chart, toxicity form and DRRs were all available; parallel opposed fields (no multiple fields) were used for both the initial and off cord/cone down fields; and an equivalent dose of 45.0 Gy or more was delivered.
  • Seventy-eight pts had Stage III; 32, Stage IV, and the remainder, Stages I, II, or recurrent lung cancer (85 non-small cell and 18, small cell).
  • Seventy-four pts were treated with definitive intent.
  • Chemotherapy was given concurrently with RT in 58 pts (in 7 pts, with twice daily, or b.i.d., RT) and as induction treatment, in 11.
  • Only 2 pts required a treatment break of more than 1 week.
  • Median total and equivalent RT doses, fraction size, and anterior esophageal length were as follows: 59.9 Gy, 59.9 Gy, 2.0 Gy, and 14 cm (range, 4.2-21).
  • The mean EI for all pts; pts treated with standard RT alone; induction chemotherapy and standard RT; concurrent chemotherapy and standard (QD) RT; and b.i.d.
  • RT with concurrent chemotherapy, was 41.
  • Three pts developed an esophageal stricture within 3 months beginning RT.
  • In multivariate analysis, the following factors were significantly associated with increasing EI: concurrent chemotherapy with QD RT and concurrent chemotherapy with b.i.d.
  • CONCLUSION: Concurrent chemotherapy and twice daily radiotherapy, especially if combined together, were associated with the highest acute maximum esophagitis grade and esophagitis index in pts with lung cancer.
  • The duration of acute esophagitis was also longest in the concurrent chemotherapy/twice daily radiotherapy group.
  • [MeSH-major] Esophagitis / etiology. Esophagus / drug effects. Esophagus / radiation effects. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Area Under Curve. Combined Modality Therapy. Female. Forecasting. Humans. Male. Middle Aged. Prospective Studies. Radiotherapy Dosage. Severity of Illness Index. Sex Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11020565.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


22. Juergens RA, Brahmer JR: Adjuvant treatment in non-small cell lung cancer: Where are we now? J Natl Compr Canc Netw; 2006 Jul;4(6):595-600
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant treatment in non-small cell lung cancer: Where are we now?
  • Lung cancer is the most common cancer worldwide, accounting for 1.2 million new cases annually.
  • Despite aggressive local management of patients diagnosed with early-stage disease (stages I-IIIA), more than half of patients who have undergone surgical resection will die from complications caused by recurrent lung cancer.
  • Over the past 5 years, results from several large trials assessing the use of adjuvant platinum-based chemotherapy in non-small cell lung cancer have become available.
  • Cisplatin-based therapy has now been shown to provide a significant survival benefit in several trials and recent meta-analyses.
  • These data have changed the paradigm for how early-stage lung cancer is managed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Prognosis. Survival Rate


23. Lutz S, Norrell R, Bertucio C, Kachnic L, Johnson C, Arthur D, Schwarz M, Palardy G: Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: a prospective study using the Lung Cancer Symptom Scale in a community hospital. J Palliat Med; 2001;4(2):157-65
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: a prospective study using the Lung Cancer Symptom Scale in a community hospital.
  • PURPOSE: To define symptoms and therapeutic requirements for patients with metastatic or locally recurrent lung cancer.
  • METHODS AND MATERIALS: Data were collected from 69 consecutive patients with locally advanced lung cancer seen in consultation at a radiation oncology facility serving a community hospital in Virginia.
  • The Lung Cancer Symptom Scale, a validated quality of life instrument, measured the incidence of symptoms in this group.
  • Fifty-seven patients received 81 courses of radiation therapy, 33 directed at thoracic disease and 48 delivered to sites of metastasis.
  • Thirty-three percent of those who received radiation therapy required treatment to more than one anatomic site.
  • Every patient was symptomatic at the time of consultation, with the number (p = 0.001) and severity (p = 0.001) of symptoms they suffered worse in the patient group seen 0 to 3 months prior to death rather than 4 to 6 months prior to death.
  • CONCLUSIONS: Patients with advanced lung cancer suffer frequent and severe symptoms that worsen in the final months of life.
  • The appropriate timing and combination of radiotherapy and chemotherapy are yet to be resolved.
  • Future studies will require use of validated quality of life instruments to better catalogue palliation and treatment toxicity.
  • [MeSH-major] Anorexia / classification. Anorexia / etiology. Bone Neoplasms / complications. Bone Neoplasms / secondary. Brain Neoplasms / complications. Brain Neoplasms / secondary. Chest Pain / classification. Chest Pain / etiology. Cough / classification. Cough / etiology. Dyspnea / classification. Dyspnea / etiology. Fatigue / classification. Fatigue / etiology. Hemoptysis / classification. Hemoptysis / etiology. Lung Neoplasms / pathology. Neoplasm Recurrence, Local / complications. Quality of Life. Severity of Illness Index
  • [MeSH-minor] Aged. Combined Modality Therapy. Cross-Sectional Studies. Female. Hospitals, Community. Humans. Incidence. Male. Palliative Care / methods. Prospective Studies. Survival Analysis. Time Factors. Treatment Outcome. Virginia / epidemiology


24. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol; 2005 Apr 10;23(11):2513-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
  • PURPOSE: To evaluate the relationship between mutations of the epidermal growth factor receptor (EGFR) gene and the effectiveness of gefitinib treatment in patients with recurrent lung cancer after pulmonary resection.
  • PATIENTS AND METHODS: We sequenced exons 18-21 of the EGFR gene using total RNA extracted from 59 patients with lung cancer who were treated with gefitinib for recurrent lung cancer.
  • Gefitinib treatment resulted in tumor shrinkage and/or CEA decrease to less than half of the baseline level in 26 patients, tumor growth and/or CEA elevation in 24 patients, and gefitinib effect was not assessable in nine patients.
  • Female, never-smoking patients with adenocarcinoma tended to respond better to gefitinib treatment.
  • Patients with EGFR mutations survived for a longer period than those without the mutations after initiation of gefitinib treatment (P = .0053).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Point Mutation. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / physiology


25. Zimmermann FB, Molls M, Jeremic B: Treatment of recurrent disease in lung cancer. Semin Surg Oncol; 2003;21(2):122-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent disease in lung cancer.
  • Recurrence is a common event after treatment of lung cancer.
  • Retreatment options depend on previous therapies, location of recurrence, and physical condition of the patient.
  • Locoregional relapse can be treated the same way as initial lung cancer, including surgery, radiotherapy (RT), and chemotherapy (CHT), or combined treatment.
  • Approximately 1% to 2% of all recurrent lung cancer is treated with curative reoperation, with somewhat dismal results.
  • In the former case, external beam RT was particularly effective in isolated bronchial stump recurrences, with median survival time of approximately 28.5 months and a 5-year survival of approximately 31.5%.
  • In the latter case, reirradiation, generally with endobronchial brachytherapy, was successful in palliation of intrathoracic symptoms (in at least two-thirds of cases), carrying a low incidence of radiation pneumonitis (up to 5%) although cumulative doses went up to 120-150 Gy.
  • Finally, CHT has been used in relapsed/refractory advanced or metastatic non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) with the major emphasis on the third-generation drugs that show good response after previously used platinum-based CHT.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Small Cell / therapy. Lung Neoplasms / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 14508862.001).
  • [ISSN] 8756-0437
  • [Journal-full-title] Seminars in surgical oncology
  • [ISO-abbreviation] Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


26. Kondo M, Yokoyama T, Fukui T, Yoshioka H, Yokoi K, Nagasaka T, Imaizumi K, Kume H, Hasegawa Y, Shimokata K, Sekido Y: Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. Lung Cancer; 2005 Dec;50(3):385-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
  • The epidermal growth factor receptor (EGFR) gene has recently been reported to be mutated in a subset of non-small cell lung cancers (NSCLC), with the mutations being correlated with the patients' drug sensitivity to gefitinib, an EGFR kinase inhibitor.
  • In this study, we searched for EGFR mutations in patients with lung cancer using primary tumor specimens obtained at initial surgery and examined whether their recurrent tumors showed a response to gefitinib depending on the presence of the activating mutation.
  • Among 12 lung cancers that were treated with gefitinib after recurrence, we found that all four tumors which showed a response to gefitinib had an activating mutation in EGFR, whereas none of the remaining eight tumors had a mutation.
  • We also examined another 73 NSCLC specimens (47 males and 26 females; 53 adenocarcinomas and 20 non-adenocarcinomas) which were not treated with gefitinib to determine whether NSCLCs with an EGFR mutation have different clinicopathological properties and/or unique genetic alterations of the other cancer-associated genes.
  • Comparing the alterations in KRAS and P53 with the EGFR mutation, we found that 10 tumors with the KRAS mutation did not have an EGFR mutation, suggesting that each mutation occurs exclusively during the development of lung cancer.
  • These results suggest that the mutation analysis of the EGFR gene using the specimens obtained at surgery might be useful in selecting the appropriate treatment(s) for recurrent lung cancer patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / drug therapy. Lung Neoplasms / genetics. Mutation / genetics. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / etiology. Adenocarcinoma / genetics. Adenocarcinoma / surgery. Aged. Base Sequence. Combined Modality Therapy. DNA, Neoplasm / analysis. DNA, Neoplasm / genetics. Female. Gene Amplification. Genes, ras. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Sensitivity and Specificity. Sex Characteristics


27. Ab' Saber AM, Massoni Neto LM, Bianchi CP, Ctenas BB, Parra ER, Eher EM, Pereira JC, Takagaki T, Yamaguchi NH, Capelozzi VL: Neuroendocrine and biologic features of primary tumors and tissue in pulmonary large cell carcinomas. Ann Thorac Surg; 2004 Jun;77(6):1883-90
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine and biologic features of primary tumors and tissue in pulmonary large cell carcinomas.
  • BACKGROUND: Because biological behavior in lung tumors with neuroendocrine differentiation is highly dependent on cell death (apoptosis) and angiogenesis, p21(waf1/cip1) and microvessel density have been targeted as potentially useful tumor markers.
  • METHODS: We examined p21(waf1/cip1) and other markers in tissue from 61 patients with surgically excised large cell carcinomas.
  • The study outcome was survival time until death from recurrent lung cancer.
  • RESULTS: Multivariate Cox model analysis demonstrated that after surgical excision, histologic subtypes were significantly related to survival time (p = 0.02), but quantitative staining of the tumor for p21(waf1/cip1) and microvessel density added prognostic information and these variables were more strongly prognostic than histologic subtype (p = 0.00).
  • Cut points at the median staining of 3.5% and 3.0% for p21(waf1/cip1) and microvessel density, respectively, divided patients into two groups with distinctive survival times.
  • Patients with p21(waf1/cip1) staining of more than 3.5% and microvessel density staining of more than 3.0% had a median survival time of 14 months.
  • CONCLUSIONS: Tumor staining for p21(waf1/cip1) and microvessel density in resected large cell carcinomas and certain other types of lung tumors was strongly related to survival.
  • Patients with more than 3.0% staining in their tumors were at high risk of death from lung cancer and may be an appropriate target for prospective studies of adjuvant chemotherapy after surgical resection.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Carcinoma, Neuroendocrine / pathology. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15172229.001).
  • [ISSN] 0003-4975
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Isoenzymes; 0 / Membrane Proteins; 0 / Tumor Suppressor Protein p53; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


28. Semrau S, Bier A, Thierbach U, Virchow C, Ketterer P, Fietkau R: Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results. Strahlenther Onkol; 2003 Dec;179(12):823-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
  • BACKGROUND: In elderly patients, patients with multiple morbidities, and patients with a reduced general condition, the standard treatment of inoperable non-small-cell lung cancer (NSCLC) consists of either chemotherapy or radiation therapy alone and is associated with an extremely poor prognosis.
  • We therefore investigated the feasibility, toxicity, and efficacy of radiotherapy with concurrent chemotherapy using vinorelbine plus cisplatin or carboplatin in NSCLC patients at risk for treatment complications.
  • PATIENTS AND METHODS: A total of 33 patients (six women, 27 men, median age 65 years) with locally advanced, functionally inoperable pulmonary carcinomas, recurrent lung cancer or postoperative macroscopic residual tumors (R2) with an increased risk of treatment complications (WHO performance status 2/3; cardiac, renal or pulmonary failure; marked pretherapeutic weight loss; age between 71-75 years) received 12.5 mg of vinorelbine per m(2) body surface area (BSA) on days 1, 8, 15, 29, 36 and 43 plus either cisplatin 20 mg/m(2) BSA (ten patients) or carboplatin 70 mg/m(2) BSA (23 patients) on days 1-5 and 29-33 together with conventionally fractionated radiotherapy.
  • The tumor regions were irradiated with doses of up to 63 Gy (90% isodose), and potentially affected lymph nodes received doses of up to 45.0 or 50.4 Gy (90% isodose).
  • RESULTS: Briefly, 31 of 33 patients successfully completed radiation therapy and 26 received four cycles of vinorelbine plus at least two cycles of cisplatin or carboplatin.
  • The survival rates plus standard deviations were as follows: 1-year survival: 60 +/- 8%, 2-year survival: 36 +/- 9%, 3-year survival: 24 +/- 9%, median survival time: 17 months (5;29 months; 95% confidence interval [CI]), median progression-free survival: 11 months (9;13 months; 95% CI).
  • The median follow-up time was 14 months.
  • CONCLUSION: Conventionally fractionated radiochemotherapy with vinorelbine plus a platinum derivative is feasible in patients with NSCLC and increased risk of treatment complications.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Cisplatin / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Vinblastine / analogs & derivatives. Vinblastine / therapeutic use
  • [MeSH-minor] Adult. Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Carboplatin / therapeutic use. Combined Modality Therapy. Confidence Intervals. Dose Fractionation. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Particle Accelerators. Radiography, Thoracic. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Risk Factors. Survival Analysis. Time Factors. Tomography, X-Ray Computed. World Health Organization

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14652671.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


29. Nakagawa T, Minamiya Y, Tozawa K, Matsuzaki I, Saito H, Ogawa J: [A case of recurrent lung cancer successfully treated with vinorelbine and cisplatin]. Gan To Kagaku Ryoho; 2001 Mar;28(3):363-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent lung cancer successfully treated with vinorelbine and cisplatin].
  • A 56-year-old female underwent lobectomy with ND2a lymph node dissection for left lung cancer in April 1999.
  • She received one course of a combination of etoposide and cisplatin as adjuvant therapy, followed by oral intake of UFT.
  • She received radiation therapy (total 60 Gy) to the mediastinum.
  • In April 2000, new lung and left supraclavicular lymph node recurrences were found.
  • She received three courses of vinorelbine 20 mg/m2 (days 1, 8) and cisplatin 80 mg/m2 (day 1) followed by radiation therapy (total 50.4 Gy) to the left supraclavicular lesion.
  • After the chemotherapy, a complete response (CR) of all metastatic lesions was achieved.
  • The combination of vinorelbine and cisplatin is a useful regimen in non-small-cell lung cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lung Neoplasms / drug therapy. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11265405.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


30. Stamatis G, Fechner S, Hillejan L, Hinterthaner M, Krbek T: Repeat mediastinoscopy as a restaging procedure. Pneumologie; 2005 Dec;59(12):862-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeat mediastinoscopy as a restaging procedure.
  • BACKGROUND: Repeat cervical mediastinoscopy is a diagnostic surgical procedure for preoperative nodal staging in patients with insufficient first mediastinoscopy, with recurrent or second primary lung neoplasms, and following induction chemotherapy or chemo-/radiotherapy for locally advanced lung cancer.
  • The aim of this study was to critically analyse indications, technical characteristics, intra- and postoperative complications, also to define selection criteria for patients with a higher probability of successful complete resection.
  • MATERIAL AND METHODS: 279 patients with lung cancer (66 female and 213 male patients, mean age 58 years, range 28 to 78 years) underwent repeat mediastinoscopy from 1968 to 2004, 12 because of inadequate first procedure (group A), 67 because of recurrent lung cancer (group B) 35 because of second primary lung cancer (group C), and 165 following induction chemo-/radiotherapy for IIIa and IIIb disease (group D).
  • The interval between first and second procedure was 17 days (range, 12 - 38) in group A, 14 months (range, 5 - 29) in group B, 27 months (range, 19 - 124) in group C, and 132 days (range, 113 - 145) in group D.
  • RESULTS: No intra- or postoperative deaths were observed, 7 patients developed minor complications.
  • Of the 116 patients with N2, and 49 with N3 disease before induction treatment (group D), repeat mediastinoscopy showed 126 N0, 20 N2 and 14 N3 status.
  • CONCLUSION: Repeat mediastinoscopy is a safe explorative procedure for the restaging of patients with primary locally advanced, recurrent or second primary lung cancer.
  • In patients after induction treatment it is, however, less sensitive than the primary mediastinoscopy because of adhesions and fibrotic tissue.
  • [MeSH-major] Lung Neoplasms / pathology. Mediastinoscopy. Neoplasm Staging
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Preoperative Care. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16379055.001).
  • [ISSN] 0934-8387
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Suzuki H, Shirane K, Nasu H, Muto O, Nakagawa T, Ogawa J: [A case of recurrent lung cancer successfully treated with vinorelbine and cisplatin/carboplatin]. Gan To Kagaku Ryoho; 2003 Jul;30(7):981-4
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent lung cancer successfully treated with vinorelbine and cisplatin/carboplatin].
  • A 73-year-old male underwent lobectomy with ND2a lymph node dissection and resection of the superior vena cava for right lung cancer in December 1998 at Akita University Hospital.
  • He received 1 course of a combination of cisplatin (CDDP) and etoposide (ETP) as postoperative adjuvant therapy.
  • In March 2001, he again underwent partial resection of the right lung (S8) due to recurrence.
  • In December 2001, a new left lung metastatic tumor was found.
  • After the chemotherapy, a complete response (CR) of metastatic lesions was achieved.
  • The combination of vinorelbine and platinum agent (CDDP/CBDCA) is a useful regimen in treating recurrent non-small-cell lung cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Aged. Alopecia / chemically induced. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Humans. Lymph Node Excision. Male. Nausea / chemically induced. Neutropenia / chemically induced. Pneumonectomy. Remission Induction. Vomiting, Anticipatory / etiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12894714.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


32. Chu XH, Zhang X, Wang S, Lu XK, Wang XQ, Wang KJ: [Clinical analysis of completion pneumonectomy for pulmonary disease]. Zhonghua Wai Ke Za Zhi; 2007 Aug 15;45(16):1132-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of completion pneumonectomy for pulmonary disease].
  • OBJECTIVE: Completion pneumonectomy (CP) is widely known to be associated with a high morbidity and mortality.
  • Lung malignancy accounted for 22 of these cases in which the indication included local recurrence in 18, second primary tumors in 2 and primary malignancies that developed after right upper lobectomies for pulmonary tuberculoma and pulmonary cyst respectively in 2 cases.
  • There were 16 of 20 lung cancer patients receiving postoperative chemotherapy and 3 with positive residues having radiotherapy.
  • The mean interval between the two procedures was 65 months for the whole group (5.5-360) and 32 months for lung cancer patients (5.5-120).
  • Two patients had right pulmonary artery injured.
  • Actuarial 1-, 3-, 5-year survival rates from the time of completion pneumonectomy for patients with lung cancer were 77.3%, 50.0% and 29.4%.
  • And 1-, 3-, 5-year survival rates for patients with recurrent lung cancer were 72.2%, 47.1% and 29.4%.
  • For patients with local recurrence, first and second primary bronchogenic carcinoma as well as benign pulmonary disease, treatment should be surgical when a less invasive procedure is not available and the patients are in good health.
  • [MeSH-major] Pneumonectomy / methods. Postoperative Complications / therapy
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Lung Diseases / surgery. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pulmonary Disease.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18005620.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


33. Iwazawa T, Matsui S, Ohnishi T, Kanoh T, Kimura Y, Tono T, Nakano Y, Yano H, Nakamura S, Monden T: [Two cases of recurrent lung cancer successfully treated with concurrent radiochemotherapy with vinorelbine plus cisplatin]. Gan To Kagaku Ryoho; 2004 Oct;31(10):1543-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of recurrent lung cancer successfully treated with concurrent radiochemotherapy with vinorelbine plus cisplatin].
  • Case 1:A 62-year-old man, who had undergone right upper lobectomy for lung squamous cell carcinoma (pT2pN2M0, stage IIA) 4 months earlier, was diagnosed as mediastinal lymph node recurrence by chest CT.
  • Case 2: A 63-year-old woman, who had undergone right middle-lower lobectomy for lung squamous cell carcinoma (pT2pN1M0, stage IIB) 16 months earlier, was diagnosed as hilar lymph node recurrence by chest CT.
  • Both patients underwent radiochemotherapy with 2 cycles of cisplatin (CDDP) 80 mg/m2 on day 1 and vinorelbine (VNR) 15 mg/m2 on day 1 and another day (day 8-16), and concurrent radiation (60 Gy/30 fr) for mediastinum.
  • After this treatment, a partial response (PR) in case 1 and a complete response (CR) in case 2 were achieved, and neither patient showed any relapse after 3 years of the treatment.
  • Concurrent radiochemotherapy with cisplatin and vinorelbine is considered effective without serious side effects for postoperative recurrence in localized mediastinal lymph nodes of non-small-cell lung cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Lymph Nodes / pathology. Vinblastine / analogs & derivatives
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Lymphatic Metastasis. Male. Mediastinum. Middle Aged. Pneumonectomy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15508447.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


34. Matsushima S, Horiguchi Y, Honda T, Fujii S, Okano T, Tanabe M, Wakayama T, Hashimoto T, Yancey KB: A case of anti-epiligrin cicatricial pemphigoid associated with lung carcinoma and severe laryngeal stenosis: review of Japanese cases and evaluation of risk for internal malignancy. J Dermatol; 2004 Jan;31(1):10-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of anti-epiligrin cicatricial pemphigoid associated with lung carcinoma and severe laryngeal stenosis: review of Japanese cases and evaluation of risk for internal malignancy.
  • A 68-year-old Japanese male with a five-year-history of lung carcinoma showed recurrent blisters and erosions on the oral and genital mucosae and the skin.
  • Although no new skin lesions appeared, he died of lung carcinoma five months after the tracheostomy.
  • [MeSH-major] Autoantibodies / immunology. Cell Adhesion Molecules / immunology. Laryngostenosis / diagnosis. Lung Neoplasms / complications. Pemphigoid, Benign Mucous Membrane / immunology. Pemphigoid, Benign Mucous Membrane / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Drug Therapy, Combination. Fatal Outcome. Humans. Immunohistochemistry. Laryngoscopy / methods. Male. Risk Assessment. Severity of Illness Index. Tracheostomy / methods

  • Genetic Alliance. consumer health - Cicatricial Pemphigoid.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14739497.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Cell Adhesion Molecules; 0 / kalinin
  • [Number-of-references] 24
  •  go-up   go-down






Advertisement